Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18419381rdf:typepubmed:Citationlld:pubmed
pubmed-article:18419381lifeskim:mentionsumls-concept:C0008049lld:lifeskim
pubmed-article:18419381lifeskim:mentionsumls-concept:C0012652lld:lifeskim
pubmed-article:18419381lifeskim:mentionsumls-concept:C0042196lld:lifeskim
pubmed-article:18419381lifeskim:mentionsumls-concept:C0332197lld:lifeskim
pubmed-article:18419381lifeskim:mentionsumls-concept:C0805586lld:lifeskim
pubmed-article:18419381lifeskim:mentionsumls-concept:C0205547lld:lifeskim
pubmed-article:18419381pubmed:dateCreated2008-4-18lld:pubmed
pubmed-article:18419381pubmed:abstractTextIn June 2005, the Advisory Committee on Immunization Practices (ACIP) recommended administering a second dose of varicella vaccine during outbreaks, supplementing the routine 1-dose requirement. From October 2005 to January 2006, a varicella outbreak occurred in Maine in a highly vaccinated elementary school population. We investigated the outbreak, held a school-based vaccination clinic, and assessed costs in implementing ACIP's outbreak-response recommendation. Parents completed questionnaires and case investigation interviews. Personnel at the Maine Center for Disease Control and Prevention, the school in which the outbreak occurred ("school A"), and physician offices completed economic surveys. Forty-eight cases occurred, with no hospitalizations or deaths. Vaccine effectiveness was 86.6% (95% confidence interval, 82.0%-90.1%). Of 240 eligible students, 132 (55.0%) received second-dose vaccination. Implementing ACIP's outbreak-response recommendation was challenging and cost approximately $26,875. Additionally, the routine 1-dose varicella vaccination policy did not confer adequate population immunity to prevent this outbreak. These findings support ACIP's June 2007 recommendation for a routine 2-dose varicella vaccination program.lld:pubmed
pubmed-article:18419381pubmed:languageenglld:pubmed
pubmed-article:18419381pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18419381pubmed:citationSubsetAIMlld:pubmed
pubmed-article:18419381pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18419381pubmed:statusMEDLINElld:pubmed
pubmed-article:18419381pubmed:monthMarlld:pubmed
pubmed-article:18419381pubmed:issn0022-1899lld:pubmed
pubmed-article:18419381pubmed:authorpubmed-author:GensheimerKat...lld:pubmed
pubmed-article:18419381pubmed:authorpubmed-author:ReynoldsMered...lld:pubmed
pubmed-article:18419381pubmed:authorpubmed-author:GurisDalyaDlld:pubmed
pubmed-article:18419381pubmed:authorpubmed-author:SchmidD...lld:pubmed
pubmed-article:18419381pubmed:authorpubmed-author:AndersonMered...lld:pubmed
pubmed-article:18419381pubmed:authorpubmed-author:LeungJessicaJlld:pubmed
pubmed-article:18419381pubmed:authorpubmed-author:Ortega-Sanche...lld:pubmed
pubmed-article:18419381pubmed:authorpubmed-author:ParkerAmy AAAlld:pubmed
pubmed-article:18419381pubmed:authorpubmed-author:ReyAraceliAlld:pubmed
pubmed-article:18419381pubmed:issnTypePrintlld:pubmed
pubmed-article:18419381pubmed:day1lld:pubmed
pubmed-article:18419381pubmed:volume197 Suppl 2lld:pubmed
pubmed-article:18419381pubmed:ownerNLMlld:pubmed
pubmed-article:18419381pubmed:authorsCompleteYlld:pubmed
pubmed-article:18419381pubmed:paginationS101-7lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:meshHeadingpubmed-meshheading:18419381...lld:pubmed
pubmed-article:18419381pubmed:year2008lld:pubmed
pubmed-article:18419381pubmed:articleTitleChallenges to implementing second-dose varicella vaccination during an outbreak in the absence of a routine 2-dose vaccination requirement--Maine, 2006.lld:pubmed
pubmed-article:18419381pubmed:affiliationEpidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. AParker@cdc.govlld:pubmed
pubmed-article:18419381pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18419381pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18419381lld:pubmed